Holen Sie sich die Stockscreener-App
55.33
0.38%
0.2662
Schlusskurs vom Vortag:
$55.06
Offen:
$54.23
24-Stunden-Volumen:
2.22M
Relative Volume:
0.36
Marktkapitalisierung:
$9.97B
Einnahmen:
$1.36B
Nettoeinkommen (Verlust:
$-302.91M
KGV:
-32.20
EPS:
-1.7182
Netto-Cashflow:
$-219.93M
1W Leistung:
+17.47%
1M Leistung:
-5.08%
6M Leistung:
+3.10%
1J Leistung:
-9.13%
1-Tages-Spanne:
$53.00
$55.90
1-Wochen-Bereich:
$44.80
$56.60
52-Wochen-Spanne:
$40.77
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Firmenname
Tempus Ai Inc
Sektor
Branche
Telefon
800-976-5448
Adresse
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, HQY, TXG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
55.35 | 7.73B | 1.36B | -302.91M | -219.93M | -1.7182 |
VEEV
Veeva Systems Inc
|
236.88 | 31.59B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
57.80 | 14.13B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
105.59 | 8.28B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
60.02 | 5.83B | 638.78M | -22.66M | 122.18M | -0.1744 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Jefferies | Underperform |
| 2026-04-13 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-19 | Eingeleitet | Mizuho | Outperform |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-21 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-10-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-09-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-21 | Eingeleitet | BTIG Research | Buy |
| 2025-02-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | Fortgesetzt | TD Cowen | Buy |
| 2024-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-09 | Eingeleitet | Guggenheim | Buy |
| 2024-11-11 | Herabstufung | Stifel | Buy → Hold |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-08-12 | Eingeleitet | Piper Sandler | Neutral |
| 2024-07-09 | Eingeleitet | BofA Securities | Buy |
| 2024-07-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-07-09 | Eingeleitet | Longbow | Buy |
| 2024-07-09 | Eingeleitet | Loop Capital | Buy |
| 2024-07-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-07-09 | Eingeleitet | Needham | Buy |
| 2024-07-09 | Eingeleitet | Stifel | Buy |
| 2024-07-09 | Eingeleitet | TD Cowen | Buy |
| 2024-07-09 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Tempus Ai Inc Aktie (TEM) Neueste Nachrichten
Tempus AI (NASDAQ:TEM) Hits New 52-Week LowTime to Sell? - MarketBeat
Tempus AI Inc stock hits 52-week low at 41.7 USD - Investing.com Canada
Eagle Health Investments LP Takes Position in Tempus AI, Inc. $TEM - MarketBeat
TEM|Tempus AI Inc|Price:42.930|Chg%:+0.240 - TradingKey
Artificial Intelligence Stocks To Keep An Eye OnJuly 27th - MarketBeat
Tempus AI Stock (TEM) Opinions on Personalis Acquisition and Analyst Upgrades - Quiver Quantitative
Tempus AI to Acquire Personalis in $1.5 Billion Deal, Deepening Its Foothold in Cancer Monitoring - Oncodaily
Tempus AI, Inc. (TEM) Stock Analysis: Exploring the 55.94% Potential Upside and Analyst Ratings - DirectorsTalk Interviews
Tempus AI Inc (TEM) Balance Sheet - TradingKey
AI Stocks: Why Tempus AI (NASDAQ:TEM), Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrodinger (NASDAQ:SDGR) Are in Focus - Kalkine Media
Tempus AI Inc (TEM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tempus AI Inc (TEM) Income Statement - TradingKey
Alan Tan: Highlighting Ultrasensitive MRD Detection with Tempus AI at KCRS26 - Oncodaily
136,636 Shares in Tempus AI, Inc. $TEM Acquired by Aristotle Atlantic Partners LLC - MarketBeat
Tempus AI (NASDAQ:TEM) Shares Fall 19% as Attention Turns to Merger Collar - TechStock²
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Brainsway (BWAY) and Argenx Se (ARGX) - The Globe and Mail
Tempus AI Inc (TEM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tempus AI Inc (TEM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tempus AI Inc|Price:42.690|Chg%:-3.320 - TradingKey
Tempus AI (NASDAQ:TEM) Upgraded to Hold at Wall Street Zen - MarketBeat
Tempus AI stock: H.C. Wainwright reiterates Buy on MRD expansion - Investing.com UK
Tempus AI buys Personalis for $1.5B; UCSF Health, Kleiner Perkins and Doerr Capital launch health AI accelerator; Candid Health raises $120M - VatorNews
Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell? - Yahoo Finance
Tempus to acquire Personalis in $1.5 billion deal to expand MRD capabilities - DOTmed
Tempus AI stock: H.C. Wainwright reiterates Buy on MRD expansion By Investing.com - Investing.com Canada
GC Wealth Management RIA LLC Cuts Position in Tempus AI, Inc. $TEM - MarketBeat
Cathie Wood buys $8.7 million of beaten-down AI stock - thestreet.com
Artificial Intelligence Stocks To Follow NowJuly 23rd - MarketBeat
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo! Finance Canada
Tempus AI (TEM) Expected to Announce Earnings on Thursday - MarketBeat
Tempus AI (TEM) Unveils National Rollout of Pharmacogenomics Tes - GuruFocus
Tempus AI Expands Cancer Platform With Launch of ArteraAI Prostate Test For Metastatic Patients - Stocktwits
Tempus makes $1.5B bet to corner cancer-test market - thestreet.com
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring - Sahm
What's behind Tempus AI's latest 3.5% stock pullback? - Traders Union
Best Artificial Intelligence Stocks To Follow TodayJuly 22nd - MarketBeat
Why is Tempus AI stock sliding today? By Investing.com - Investing.com Canada
Tempus AI launches pharmacogenomics testing nationwide By Investing.com - Investing.com Nigeria
Tempus AI launches pharmacogenomics testing nationwide - Investing.com
Tempus Launches Test for Therapies With Nearly 30% Severe Toxicities - Stock Titan
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM) - The Globe and Mail
Tempus AI to Acquire Cancer Diagnostics Firm Personalis for approximately $1.5 Billion, Targeting MRD Market Leadership - finance.biggo.com
Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In - Yahoo Finance
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks - Sahm
Tempus to acquire Personalis, Inc. (PSNL) in cash and stock merger - Stock Titan
Tempus AI: Buy Rating Reaffirmed as Personalis Deal Strengthens MRD Position; $75 Price Target Maintained - TipRanks
Why Is Tempus AI Stock Volatile Tuesday?Personalis (NASDAQ:PSNL), Tempus AI (NASDAQ:TEM) - Benzinga
TEM, PSNL stocks are falling — why Morgan Stanley still likes Tempus AI’s Personalis deal - MSN
Tempus AI buys Personalis for $1.5 billion - grafa.com
Artificial Intelligence Stocks To Add to Your WatchlistJuly 21st - MarketBeat
Tempus AI Buys Personalis for $1.5B to Boost Cancer Monitoring - Medical Device and Diagnostic industry
Finanzdaten der Tempus Ai Inc-Aktie (TEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tempus Ai Inc-Aktie (TEM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Epstein David R | Director |
Aug 03 '26 |
Sale |
43.40 |
370 |
16,058 |
31,094 |
| Fukushima Ryan | CEO, Data |
Aug 03 '26 |
Sale |
46.19 |
23,818 |
1,100,076 |
143,945 |
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):